SELENOS

Across TCGA pan-cancer cohorts, SELENOS mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SELENOS data layer compared with 21 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SELENOS mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SELENOS expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where SELENOS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	II,III,IV	0.326	0.819	.003	42	view →
CCRCC	DFS	Median	II,III,IV	0.139	0.979	.001	31	view →
PDAC	OS	Quartile	III,IV	0.760	0.298	.010	6	view →
HNSC	DFS	Median	II,III,IV	0.775	0.558	.015	4	view →
GBM	OS	Tertile	All	0.661	0.369	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SELENOS–LUAD (OS)

Open the LUAD breakdown →